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1. Introduction  
The mankind is living longer due to improved quality of life, better healthcare service 
worldwide and less infant mortality. Progressive demographic ageing of the older 
population is a global process. The 80 or over age group is growing faster than any young 
segment of the older population 
1.1 Life expectancy in patients with haemophilia  
Until 1960 haemophilia was a life-threatening disease with limited treatment options as 
splints, icepacks and bed rest. With the discovery of factor concentrates the life of 
haemophilia patients changed dramatically better. They improved quality of life and 
prolong life expectancy (Mejia-Carvajal, 2006). Median life expectancy in males with severe 
haemophilia was 11 years in the early 20th century,  increased to the range of 55 to 63 years 
in the 1970s (Plug, 2006; Darby, 2007). By the early 1980s life expectancy was almost 68 years 
(Chorba, 2001; Oldenburg, 2009). By 1990s the life expectancy in US haemophiliacs dropped 
to 49 years because of HIV infections. The decline in HIV-related mortality in HIV-infected 
persons with haemophilia reflected improvements in highly active anti-retroviral therapy 
(HAART). In 2001, haemophiliac life expectancy in The Netherlands reached 67 years (74 
years for those without blood borne virus infections) and by 2007, the overall haemophilic 
life expectancy was reported to be 71 years in Italy (Plug, 2006; Tagliaferri, 2010) that is 
approaching the general male population. About 2% of haemophilia A and B patients 
surveyed in US comprehensive haemophilia treatment centres are 65 years of age or older 
and 15% are 45 years or older (Philipp, 2010).  
1.2 Quality of life in patients with haemophilia  
As haemophiliacs are reaching old age new problems are arising. Except physical problems 
we are faced today with psychological problems in older patients with haemophilia (Siboni, 
2009). They are related to family dynamics (Franchini, 2007) and early retirement. Data on 
health-related quality of life (HR-QoL) of elderly persons with haemophilia are scare. 
Quality of life has become an important issue for physicians who are treating haemophilia 
patients and an increasing number of studies have analysed the HR-QoL in this population, 
using specific instruments for its measurement Haemo-QoL (Gringeri, 2006). Results from 
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multicentre study conducted in Italy in a cohort of elderly haemophiliacs (≥ 65 years) have 
shown similar cognitive status as elderly non-haemophiliacs. Persons with haemophilia 
report depression and lower health-related quality of life (Siboni, 2009). These results are 
very important because, the health status of elderly persons with haemophilia was 
evaluated in a case control study. These data are consistent with studies on HR-QoL in 
younger haemophilia patients (Scalone, 2006).  
2. Characteristics of older haemophiliac 
The life expectancy in persons with haemophilia is increasing and reaching almost that of  e 
general population (Mejia-Carvajal, 2006). In many haemophilia centres, especially those in 
well-developed countries, old haemophilia person is not a rarity. Haematologists have little 
experience in managing the age related comorbidities of elderly haemophiliacs and the data 
are very rare. There is no evidence-based information to guide clinicians and help them to 
solve the problems. Population of haemophiliacs is aging slowly, giving us time to solve the 
problems and generate high quality data. 
2.1 Haemophilia related comorbidities and age related diseases 
Haemophilia patients with increased age suffer the same diseases as the normal male 
population, especially in well developed countries with sufficient quantity of factor 
concentrate (Franchini, 2009). Aging is bringing to haemophilia patients not only 
haemophilia related complications (arthropathy and chronic viral infections) or 
comorbidities but also age related diseases (cardiovascular disease, malignancy, renal 
disease, osteoporosis, mental diseases, etc.). About 88% of the general population over the 
age of 65 years have one or more chronic medical conditions (Hoffman, 1995). Today, 
clinical  experience  about comorbidities in elderly haemophiliacs and their influence on the 
primary disorder, haemophilia are lacking. 
2.1.1 Arthropathy  
Haemophilia A and B are characterized in the most severe form with spontaneous bleeding 
into joints and muscles. Prophylactic therapy with factor concentrates has been shown, if 
started early, reduce the burden of haemophilic arthropathy (Dolan, 2010; Kulkarni, 2003). 
Administration of factor concentrate on regular basis, prophylactically demonstrated in US 
Joint Outcome study benefits in preventing joint damage and bleeding episodes, compared 
with on-demand use in children (Manco-Johnson, 2007). It is known that many adults with 
severe haemophilia over the age of 65 and older did not have adequate access for regular 
treatment until adulthood. They have established haemophilic arthropathy with typical joint 
deformity, muscle weakness and impaired proprioception (Nilsson, 1992; Siboni, 2009) that 
influence the quality of life (limitations in their daily activities, etc.). Italian study was the 
first to evaluate the general health status in patients with severe haemophilia, aged ≥65 
years and were compared with elderly men without bleeding disorders matched for age, 
sex, geography and social status. Almost all patients with haemophilia had arthropathy, 
except two. More than half were affected in all six joints considered (57%): only one patient 
was affected in one joint only, five in three joints and the remaining 28 patients in more than 
three joints. Haemophilia patients had higher pain score and significant difference was 
found in the orthopaedic score between the two groups. No statistical difference was found 
for the number of surgical procedures but joint arthroplasty was performed in 46% of 
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patients with haemophilia and 7% in non-haemophilic (Siboni, et al 2009). Orthopaedic 
surgical procedures are usually ankle arthrodesis, osteotomy, hip and knee arthroplasty. 
Indications for such procedures are chronic permanent pain in arthropathic joint, disability 
and ineffectiveness of conservative management. There will be more revision operations 
that have a higher risk of bleeding, in older haemophilia patients who had their first 
arthroplasty about 15 years earlier. Perioperative treatment for orthopaedic surgery is 
administration of factor concentrate to achieve normal activity of F VIII as well as protects 
from development of thromboembolism.  
Two approaches are applying for thromboprophylaxis: administration of low molecular 
weight heparins shortly after operation and under the cover of factor concentrates or using 
mechanical methods with early ambulation. Thromboprophylaxis is still a big question with 
certain controversial. Proprioceptive loss seen in elderly haemophiliacs could increase the 
risk of falls (Street, 2006). About 70% of elderly people with haemophilia had a high risk of 
falling, spontaneously or after tripling on obstacles (Siboni, 2009). Physical therapy is 
essential part of comprehensive care for haemophiliacs trying to preserve function of the 
joint and improve quality of life. They have to do functional training (hydrotherapy, 
walking climbing stairs, cycling, etc). Osteopenia and osteoporosis can cause increased 
number of serious injuries and fracture after falls (Wallny, 2007). Painful haemophilic 
arthropathy with reduced mobility and lack of activity may lead to a reduction of bone 
mass. Therefore it is recommended weight-bearing physical activities or sports, but with 
surgery to mobilize the patient. Calcium and vitamin D supplementation are recommended 
(Kovacs, 2008). Secondary prophylaxis based on two to three infusions of factor concentrates 
per week in adult patients with haemophilia and with few older patients ≥ 65 years in small 
retrospective studies showed marked reduction in frequency of bleeding (Tagliaferri, 2008) 
but athropathy is worsening. Prophylaxis in elderly persons with haemophilia is justified  
and whenever possible to carry out it is improving their quality of life. 
2.1.2 Chronic blood borne infections 
Chronic viral infections such as HIV, hepatitis B (HBV) and hepatitis C (HCV) virus are still 
prevalent in a subgroup of adult haemophilia patients. It is also important to emphasis the 
risk of development of liver cancer on the background of chronic HCV infection; 
particularly with genotype 1 and HIV confection, who failed to achieve a sustained viral 
response with pegylated interferon and ribavirin (Posthouwer, 2007). Many of them will 
develop liver cirrhosis and subsequent hepatocellular carcinoma (HCC) (Posthouwer, 2007, 
Konkle, 2009, Siboni, 2009). Hepatocellular cancer is the most prevalent cancer in the older 
haemophilia patients. Therefore, surveillance program with periodic ultrasound screening is 
recommended to detect HCC earlier in people with haemophilia and cirrhosis. Therefore, 
close surveillance with gastroenterologists in collaboration with hematologist should be 
carried out to prevent such bleeding complications.  
In HIV-infected hemophilic patients, combined antiretroviral therapy (cART) significantly 
improved survival rate comparing to period before the introduction of this treatment in the 
middle 1990s. cART has also reduced the previously frequent incidence of non-Hodgkin 
lymphomas (Ragni, 1993, Wilde, 2002). However, cART increases the risk of the metabolic 
syndrome, diabetes, renal insufficiency, and atherosclerotic cardiovascular disease in non-
hemophilia patients (Lundgren et al., 2008). It is likely to suspect that cART will induce the 
same long-term complications among HIV-infected elderly patients with hemophilia, 
although there are very rare data about the long-term outcome of such patient subgroup. 
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Moreover, chronic viral infections such as HCV and HIV can also alter the complex 
inflammatory process of atherosclerosis and coronary heart disease by itself. Checking 
serum lipid, glucose, and creatinine at regular intervals is suggested.   
In HIV-infected hemophilic patients, combined antiretroviral therapy (cART) significantly 
improved survival rate comparing to period before the introduction of this treatment in the 
middle 1990s. cART has also reduced the previously frequent incidence of non-Hodgkin 
lymphomas (Ragni, 1993, Wilde, 2002). However, cART increases the risk of the metabolic 
syndrome, diabetes, renal insufficiency, and atherosclerotic cardiovascular disease in non-
hemophilia patients (Lundgren, 2008). It is likely to suspect that cART will induce the same 
long-term complications among HIV-infected elderly patients with haemophilia, although 
there are very rare data about the long-term outcome of such patient subgroup. Moreover, 
chronic viral infections such as HCV and HIV can also alter the complex inflammatory 
process of atherosclerosis and coronary heart disease by itself. Therefore, checking serum 
lipid, glucose, and creatinine at regular intervals is suggested. 
2.1.3 Inhibitors  
Data from large nationwide haemophilia population (Darby, 2004) provided estimates of the 
rate of development of inhibitors and showed the cumulative risk of haemophilia A 
inhibitors at 50 years is 30% and 36% at 75 years. Patients with milder forms of haemophilia 
may develop inhibitors at advanced age when they receive intensive replacement therapy 
preoperatively or for invasive procedures. Other risk factors for inhibitor development in 
mild to moderate haemophilia are certain mutations, like Arg531Cys and exposure to 
continuous infusion of factor concentrate (Eckhart, 2009).  
The treatment of acute bleeding in older severe haemophilia A patients with inhibitors is 
administration of activated prothrombin concentrate (APCC) and recombinant factor VIIa. 
Rapid control of bleeding is the key to reducing bleeding complications and therebay 
preserving joint and musculoskeletal function in haemophilia patients with inhibitors 
(Šalek, 2011). Risk of thrombotic complication with bypassing agents is a question especially 
with advanced age. There are a few articles about safe administration of rFVIIa to elderly 
haemophilia patients with inhibitors (Rivolta, 2009; Leebeck, 2004). There is just one report 
about the successful immune tolerance induction (ITI) in one old haemophilia patient (60-
years old) and high responding inhibitors (Rivolta, 2009). Review article published by 
Franchini (Franchini, 2008) found that about half of the haemophilia patients with inhibitors 
resistant to previous immune tolerance regimens are rescued by rituximab treatment. The 
highest probability to obtain complete response to rituximab was observed for adult 
haemophilia patients with mild to moderate haemophilia with median age of 50.5 years. 
Presence of inhibitors in older patient with haemophilia and their treatment represent still 
today a significant challenge.  
2.1.4 Renal disease (urogenital disease) 
Chronic kidney disease probably develops with increasing prevalence among older people 
with hemophilia because of multiple concomitant risk factors such as HIV infection and 
combined antiretroviral treatment, hematuria, structural renal damage, and use of 
antifibrinolytic drug. (Kulkarni, 2003).  
Another important aspect of aging is erectile dysfunction resulting not only from the normal 
aging process, but also from co-morbidities such as painful chronic joint damage affecting 
sexual desire and conditions that affect erectile function, such as artheriosclerosis and 
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hypertension (Gianotten, 2009). The use of multiple drugs for the treatment may also 
compromise sexual function. Prostatic hypertrophy is also a frequent problem in elderly 
people with haemophilia. Genitourinary diseases and prostatic hypertrophy may facilitate 
the onset of hematuria as well. 
2.1.5 Malignancy 
The literature data showed clearly that liver cancer and lymphoma represent the most 
prevalent malignancy in haemophilia population. They are usually associated with HCV 
and HIV positivity. Hepatocellular carcinoma is very important cause of death among 
haemophiliacs with a reported standardized mortality ratio of 17.2 (Plug, 2006) and 13.51 
(Darby, 2007). Risk factors for hepatocellular carcinoma assessed in multicentre Italian study 
were presence of liver cirrhosis, elevated alpha fetoprotein, current HCV infection and age 
over 45 (Tradati, 1998). There are many studies which do not found an increased incidence 
of other malignancies in haemophilia compared with general population. Moreover, two 
population studies found a lower incidence of cancer in severe haemophilia (Walker, 1998; 
Darby, 2007). In vitro study has shown that congenital prothrombotic disorders facilitate 
metastasis. Haemophiliac mice form less metastasis from experimental melanomas what 
could be explained with less formation of thrombin (Bruggemann, 2008). It seems that 
congenital bleeding disorders may have a protective effect against formation of metastasis 
on murine cells (Langer, 2006). Elderly patients with haemophilia will develop malignancies 
like normal elderly population; prostate, skin and gastrointestinal cancer (Franchini, 2009).  
Treatment schemes for malignant tumours in older haemophilia patients are similar to non-
haemophiliac although the inherited coagulation disorder might increase the risk of 
bleeding during chemo and radiotherapy. Factor replacement therapy is needed for invasive 
diagnostic and therapeutic procedures and prophylactic factor administration is mandatory 
for surgery (Mannucci, 2009; Dolan, 2010). At the moment it is not completely clear how 
intensive replacement therapy should be in a situation of treatment carcinoma in elderly 
haemophiliacs. There are no recommendations about optimal treatment of elderly 
haemophiliac with malignancy, except some case reports (Lambert, 2008; Toyoda, 2001).  
Our group publish a case of 51-year old patient with severe haemophilia A with low-titre 
inhibitors and multiple relapsing non-melanoma skin cancer. The management of such 
patients could be very intriguing and require a multidisciplinary approach (Zupančić Šalek, 
2009). Age indicated screening tests for malignoma of prostate and colon are justified also in 
the population of elderly haemophiliacs but under the cover of prophylactic treatment with 
factor concentrates. Very important fact about haemophilia patients is that they are usually 
excluded from participating in clinical trials which are evaluating new anticancer drugs 
because of the potential adverse effects of haemostatic system. Definitely, treatment of older 
haemophilia patient with malignancy is a complex issue.  
2.1.6 Pain control 
Pain control is extremely important for improvement quality of life among people with 
haemophilia, especially due to chronic joint damage. Haemophilic arthropathy and related 
morbidity is still present major concern among haemophilic population. Therefore, chronic 
pain is prevalent in the elderly people with haemophilia, and even drug addiction is not 
rare. Possible adverse effects of widely used paracetamol and non-steroidal anti-
inflammatory drugs (NSAIDs) may become more clinically significant with aging: 
gastroduodenal toxicity, paracetamol-associated liver dysfunction (particularly associated 
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with chronic liver disease due to excessive alcohol consumption and/or viral infections), 
hypertension, and renal insufficiency (Davies et al., 2006). However, paracetamol is still the 
first choice for pain management among haemophilia patients, and when it is not effective 
to control pain, cyclo-oxygenase-2 (COX-2) inhibitors are preferred to NSAIDs (Mannucci, 
2009). Other possibilities are narcotics such as codeine- and morphine-containing drugs 
(Mannucci, 2009). Moreover, additional useful option for pain control is referral to a pain 
management clinic, as well as pre-emptive physiotherapy and hydrotherapy to improve 
joint stability. 
2.1.7 Cardiovascular disease in elderly patients with hemophilia 
Haemophilia is reported to be protective against development of coronary heart disease due 
to the hypocoagulable state of such patients (Rosendaal, 1990). However, people with 
haemophilia could have other common risk factors for cardiovascular diseases, such as 
hypertension, smoking, obesity, dyslipidaemia, and diabetes. Additionally, HIV infection 
and cART may per se increase the risk for metabolic and cardiovascular disease, as it was 
stated earlier. Indeed, it was reported recently an increasing number of deaths in 
haemophilia patients as a consequence of ischemic heart disease (Plug, 2006), together  
with increasing prevalence of ischemic heart disease among haemophilia patients 60 years 
of age and older (Kulkarni, 2005).  Moreover, it is important to educate haemophilia patients 
about the cardiovascular risk factors, and on the benefit of living a healthy lifestyle 
(Mannucci, 2009). 
2.2 Assessment of atherosclerotic risk factors in patients with haemophilia 
2.2.1 Introduction 
Myocardial and cerebral infarctions are the leading causes of death around the world 
(Murray, 1997). Due to its public health importance, numerous studies have examined risk 
factors for atherosclerosis. Due to rare reports about risk factors in haemophilia patients we 
present data from risk assessment in haemophiliacs. 
2.2.2 Subjects and methods 
During a 10-year period 410 patients with haemophilia A and B were followed in National  
Haemophilia Centre in University Hospital. Eight died, two of infection, three of bleeding, 
two of liver disease and one of malignancy. None of them died due to coronary or 
cerebrovascular diseases and there were no drop-outs during the follow-up. Of the 
surviving 402 patients, 336 (84%) had haemophilia A and 66 (16%) haemophilia B. A cohort 
of 117 haemophilia patients who attended regular check-ups consented to participate in our 
risk factors study. 104 (89%) had haemophilia A  and 13 (11%) haemophilia B. Control group 
consists of 48 age-adjusted healthy male non-haemophiliac volunteers who did not have 
anamnestic or clinical signs and symptoms of coronary heart disease or other complications 
of atherosclerosis.  
Body mass index was calculated and patients were considered to have normal weight if 
their BMI was below 25, overweight if the BMI was 25-29.9 and  obese if the BMI was 3.0 or 
higher (Flegal, 1998). Blood pressure was measured and according to the WHO/ISH criteria, 
patents were considered having arterial hypertension if their systolic blood pressure was 
140 mmHg or higher, diastolic blood pressure was 90 mmHg or higher of if they were 
taking antihypertensive medications(WHO/ISH, 1999). Serum concentrations of glucose, 
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creatinine, uric acid, fibrinogen, total cholesterol, triglycerides, HDL cholesterol and LDL 
cholesterol were determined using standard methods and commercially available reagents 
(Horvat, 2003). Homocysteine concentration and lipoprotein (a) was also determined. 
Framingham risk index was determined as described by Grundy and co-workers (Grundy, 
1999). The ten-year risk of developing coronary heart disease in individuals without 
symptomatic atherosclerosis is determined taking into account their sex, age, total-
cholesterol, HDL-cholesterol, systolic blood pressure, treatment of arterial hypertension and 
smoking. Four risk levels are recognised: low, moderate, high and very high.  The expected 
incidence of coronary and ischaemic cerebrovascular disease morbidity and mortality for 
patents with haemophilia was calculated as follows. The number and age for male patents 
discharged from Croatian hospitals with diagnosis of myocardial infarction, coronary heart 
disease and cerebrovascular infarction were abstracted from official publications of the 
Croatian Institute for Public Health (Ljubičić, 2002). Thus calculated age adjusted morbidity 
and mortality rates were used to determine the expected morbidity and mortality of patients 
with haemophilia during the 10-year observation period.  
2.2.3 Results  
The tested cohort did not differ from the whole group of patients with haemophilia in 
respect to age and haemophilia type. More patients with haemophilia than control subjects 
smoked (44 vrs. 33%). This difference was even more pronounced in the group of patients 
with severe haemophilia (46%) but did not reach statistical significance. Patients with 
haemophilia had slightly lower BMI than normal controls. Again this difference was more 
pronounced in patients with severe disease but again, did not reach statistical significance. 
The incidence of abnormal BMI was similar in all analysed groups. Patients with 
haemophilia had similar systolic but higher diastolic blood pressure than control subjects. 
This difference was significant for the subgroup of patients with severe disease but not for 
the subgroup of patients with moderate or mild disease. The incidence of diastolic 
hypertension was higher in the group of patients with haemophilia than in the control 
group. Again, this difference was highly significant for the subgroup with severe disease but 
barely failed to reach significance for the subgroup of patients with moderate or mild 
disease. The incidence of systolic hypertension was higher in the group of patients with 
severe disease than in the control group (Figure 1.) The difference between all subjects with 
haemophilia and control subjects barely failed to reach statistical significance. These data 
suggest that arterial hypertension is more frequent in patients with haemophilia, especially 
in those with severe disease. 
Patients with haemophilia did not differ from control subjects in respect to blood glucose, 
fibrinogen, uric acid and homocysteine concentrations, but they had lower total cholesterol, 
triglycerides and creatinine concentrations. The difference was even more pronounced in 
the subgroup of patients with severe haemophilia who also had lower LDL-cholesterol than 
controls. Patients with mild to moderate disease had higher HDL-cholesterol than controls. 
The incidence of abnormal serum glucose, fibrinogen, creatinine, uric acid and 
homocysteine levels was similar between groups. Controls had more frequently abnormal 
total cholesterol, HDL-cholesterol and triglycerides concentrations than patients with 
haemophilia. They had also more often abnormal total-cholesterol, LDL- cholesterol and 
triglycerides concentrations than patients with severe disease; an abnormal HDL-cholesterol 
and triglycerides concentrations than patients with mild to moderate disease.  
www.intechopen.com
 
Hemophilia 
 
118 
 
Fig. 1. Frequency of arterial hypertension in patients with haemophilia and control (Legend: 
red column: systolic blood pressure; blue column: diastolic blood pressure; RRs – systolic 
blood pressure; RRd dyastolic blood pressure, H: all haemophilia patients, H-1: severe 
haemophilia patients; H-II moderate haemophilia patients; H-III mild haemophilia patients) 
This indicates that patients with haemophilia, especially those with severe disease have 
lower cholesterol and triglyceride concentrations than control subjects. In patients with mild 
to moderate haemophilia the increase in total cholesterol is accompanied by an increase in 
HDL-cholesterol, resulting in a similarly low-risk lipid profile as in those with severe 
disease. 
 
 
Fig. 2. Risk assessment of coronary heart disease according to LDL/HDL ratio. (Legend: H-I: 
severe haemophilia; H-II/III: mild and moderate haemophilia; H: all haemophilias patients 
and K .controls.) 
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Framingham risk index. The distribution of risk groups did not differ between patients with 
haemophilia and control subjects. However, some of the patients with severe disease had a 
high or very high risk of developing coronary heart disease. None such cases could be seen 
in the control group (Figure 2). 
If the morbidity of myocardial infarction and ischaemic cerebrovascular infarction, 
calculated as described in “Methods” section, would be the same in patients with 
haemophilia as it is in the general Croatian population, during the ten-year observation 
period 18 patients would be expected to develop myocardial infarction and 10 ischaemic 
cerebrovascular infarction. However, none occurred. These differences are highly 
statistically significant. If the mortality of coronary heart disease, myocardial infarction or 
cerebrovascular infarction, calculated as described in section “Methods” , would be the 
same in patients with haemophilia as it is in the general Croatian population, during the ten-
year observation period 8 patients would be expected to die of coronary heart disease, 4 of 
myocardial infarction and 4 of cerebrovascular infarction. None of them died. These 
differences are statistically significant. These data indicate that patients with haemophilia 
have a significant lower incidence of complications of atherosclerosis than the general 
population.  
The concentration of lipoprotein (a) as well as the proportion of subjects with abnormal 
levels is higher in the group of patients with haemophilia than in the controls. The 
difference is more pronounced in the subgroup of patients with mild to moderate disease, 
while the difference between patients with severe haemophilia and controls fails to reach 
statistical significance (Figure 3).  
 
 
Fig. 3. Frequency of abnormal values for homocysteine and lipoprotein (a) (Legend: H-I: 
severe haemophilia; H-II/III: mild and moderate haemophilia; H: all haemophilia patients 
and K: controls.) 
2.2.3.1 Risk factors  
Our results suggest that patients with haemophilia smoke somewhat more frequently than 
the subjects from the control group or the general Croatian population. Two studies, one 
Dutch and the other Italian study with patients with haemophilia have reached the same 
conclusion (Rosendaal et al 1990; Bilora, 1999).  This is most probably due to psychological 
changes induced by the presence of a chronic disease and the enforced sedentary life style.  
Our patients have s slightly lower BMI than healthy subjects. The same was found in the 
Dutch study. Again, this is more probably a result of reduced muscle mass in patients with 
haemophilia, caused by their sedentary life style, than their superior health consciousness.  
www.intechopen.com
 
Hemophilia 
 
120 
The incidence of hypertension in the group of patients with haemophilia was 48%, while it 
was 20% in the control group. The latter incidence is surprisingly low, probably due to the 
fact that the control subjects had to be free from any signs and symptoms of disease due to 
atherosclerosis. An epidemiological study performed in 2 898 Croatian subjects found a 32% 
incidence of hypertension, still lower than in patients with haemophilia (Turek, 2001). The 
increase in blood pressure we observed was even more pronounced in patients with severe 
haemophilia and was already present in the youngest group aged between 18 and 29 years. 
This might suggest that haemophilia somehow causes hypertension. The underlying 
mechanisms are completely unclear and further research is needed. Renal damage is 
certainly not the cause.  
Patients with haemophilia have more favourable lipid profiles than control subjects. Again, 
similar findings were obtained by Rosendaal. Lowest cholesterol levels are seen in patients 
with severe haemophilia. In patients with milder disease total cholesterol is increased, but 
so it HDL-cholesterol, resulting in a lipid profile that is still favourable than in control 
subjects.  Since we have no reason to believe that patients with haemophilia adhere to a 
more healthy diet than average person, we agree with the explanation of Rosendaal and col. 
That this difference is due to a reduced liver synthetic capacity caused by an increased 
exposure to foreign proteins and transfusion related viral diseases.  
Increased homocyteine levels were seen in 25 % of patients with haemophilia and 23% 
control subjects. These proportions are not statistically different, but are higher than those 
published for other populations. The reason for this is not clear. 
Patient with haemophilia has increased lipoprotein (a) levels. There are reports indicating 
that lipoprotein (a) levels are reduced in haemophilia patients with AIDS. and that the 
incidence of increased lipoprotein (a) levels in children with haemophilia is not different 
from that observed in the general population (Matsuda et al 1994). There are no reports on 
the concentration of lipoprotein (a) in adult, HIV negative, patients with haemophilia. Since 
these concentrations are genetically determined and not influenced by diet, studies in other 
populations are needed to determine whether the increase is characteristic for haemophilia 
or specific for tested population (Scanu, 1992).  
2.2.3.2 Global risk assessment  
The Framingham risk index is a reliable predictor of the ten-year risk for the development of 
coronary heart disease for persons who did not have prior complications of atherosclerosis 
(Grundy, 1998). it is used in USA guidelines for arterial hypertension and 
hypercholesterolemia treatment. It is still one of the best and most validated global risk 
assessment tools for risk factors for coronary heart disease in patients with haemophilia.  
According to the Framingham risk index, patients with haemophilia are similar to the 
control group. While the global assessment is similar, there are important differences in risk 
profiles. Patients with haemophilia have more favourable lipid profiles, but tend to smoke 
and have arterial hypertension more frequent than control subjects. Still, some of the 
patients with severe haemophilia have high risk features, while none such subjects were 
found in the control group. If the difference in newly recognized risk factors, such as 
lipoprotein (a) levels, would be taken into account, the increase in risk in the haemophilia 
group would be even more pronounced.  
2.2.3.3 Coronary heart disease and cerebrovascular morbidity and mortality 
The expected coronary and cerebrovascular morbidity and mortality in the group of patients 
with haemophilia is probably underestimated. The difference between the expected and 
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observed coronary heart disease and cerebrovascular morbidity and mortality in patients 
with haemophilia is highly significant. The same phenomenon was observed by other 
authors in other countries. This indicates that patients with haemophilia have a reduced risk 
of developing and dying of myocardial infarction, coronary heart disease and ischaemic 
cerebrovascular infarction.  
2.2.4 Haemophilia and atherosclerosis  
The reduction of complications of atherosclerosis in patients with haemophilia is not due to 
a reduction in known risk factors. It is tempting to assume that the inability to produce a 
stable thrombus, i.e. haemophilia itself, is the cause. Our results and the published data 
suggest that haemophilia protects patients against atherosclerosis and complications but it is 
still not clear whether this is due only to the lack of thromboembolic incidents occurring late 
in the process of atherogenesis. 
2.3 Osteoporosis  
2.3.1 Introduction 
Since the world's population is ageing, osteoporosis has become one of the major 
socioeconomic problems in the western world. As a consequence of reduced bone mass and 
decline in neuromuscular function, the risk of osteoporotic fractures is rising with the 
advancing age, both in men and in women. Fractures of the spine, proximal femur and a 
distal forearm are described as typical for osteoporosis; nevertheless, almost all types of 
bone fractures are increased in patients with reduced bone mineral mass. Many factors 
influence bone mass accumulation in early life, and maintenance of that mass in adult age. 
including genetic factors, hormonal status, physical activity and calcium intake. Besides 
genetics, which has the highest impact on bone mass accumulation and maintenance, the 
changes of hormonal status in ageing woman have been described to have strong impact on 
bone mineral mass. 
2.3.2 Osteoporosis in haemophilia patients 
Recently, bone mineral mass has become an issue of interest in patients with haemophilia. 
Although there are only sparse data about osteoporotic fractures in haemophilia patients, 
we can expect increase in number of osteoporotic fractures in the future due to ageing of 
haemophilia population. Morbidity and mortality of osteoporotic fractures in haemophilia 
patients are very high, and those patients need special care (Rodriguez-Merchan, 2002.). 
Moreover, it has been shown that patients with haemophilia and reduced bone mass have 
lower quality of life (Khawaji, 2010.). Studies addressing bone mineral mass in haemophilia 
patients mainly focused on patients with severe haemophilia. Because haemophilia is rare 
disease, total number of studied patients is relatively low. 
2.3.3 Incidence of reduced bone mass in haemophilia patients 
The incidence of reduced mineral bone mass among patients with haemophilia differs 
between studies. Our results, in a study where we evaluated 58 patients with haemophilia, 
showed reduced bone mass in 56% of patients with haemophilia. Those results are 
comparable with findings of Nair, who described reduced bone mass in 50% of patients 
with severe haemophilia (Nair, 2007). On the other hand, some authors showed reduced 
bone mass in 86% patients with severe and moderate haemophilia (FVIII<3%) (Katsarou, 
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2009), and in 70% of patients with severe haemophilia (Gerstner, 2009, Wallny, 2007). The 
reason for difference between those results is uncertain.  
The data about incidence of reduced bone mineral mass in patients with moderate or mild 
haemophilia are sparse. Our results showed increased loss of bone mineral density in 
patients with mild and moderate haemophilia (FVIII>1%). In comparison of bone mass 
between patients with severe and patients with mild or moderate haemophilia, the 
difference was noted in values of bone mineral density measured at femoral neck, 
representing cortical bone, where patients with mild and moderate haemophilia had higher 
values (Boban, unpublished data). See Figure 4.  
 
 
Fig. 4. Prevalence of osteopenia and osteoporosis in patients with haemophilia.  
2.3.4 Physical activity  
Several risk factors for developing osteoporosis in patients with haemophilia have been 
recognized. Besides genetics, reduction of physical activity during childhood and adult age 
has been suggested to have major impact on bone metabolism in haemophilia patients. 
However, the exact pathogenesis of developing reduced bone mineral mass in haemophilia 
patients is still obscure. Patients with haemophilia seem to achieve lower peak bone mineral 
mass when compared to healthy controls. In favour of this hypothesis, studies showed 
reduced bone mineral density among children with severe haemophilia (Barnes, 2004, 
Abdelrazik , 2007., Nair, 2007., Tlacuilo-Parra, 2008.). The major impact on bone formation 
during childhood and adolescents has physical activity and, moreover, weight-bearing 
exercises. Patients with haemophilia avoid physical activity due to acute bleedings into 
joints, chronic pain, development of arthropathy, and fear of possible injury. The study 
showed that 77% of young haemophiliacs are inactive; with the high correlation of inactivity 
and reduced bone mass (Tlacuilo-Parra, 2008).  
The role of physical activity in maintaining or even improving bone mass in adult age is 
questionable. The only study that evaluated influence of physical activity on bone mass in 
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adult haemophilia patient did not show any correlation between those two parameters 
(Khawaji, 2010.). However, we must point out that patients enrolled in the mentioned study 
had normal bone mineral mass. 
2.3.5 Joint status and prophylactic therapy 
The strong relationship has been established between reduced bone mass and joint status in 
young patients with haemophilia (Abdelrazik, 2007), as well as among adult haemophiliacs 
(Nair, 2007., Katsarou, 2009.). Joint status was evaluated using clinical score as described by 
the Orthtopedic Advisory Council of the World Federation of Haemophilia (Rodriguez-
Merchan EC, 2003.) and by the Pettersson scores (Pettersson, 1994). Total joint score had 
independent prognostic value for development of bone loss (Nair, 2007., Katsarou, 2009). In 
our study number of target joints was evaluated as a prognostic factor for development of 
bone loss. No correlation was found between bone mass and number of target joints (Boban, 
unpublished data). 
Prophylactic therapy, however, seems to prevent bone mineral loss. Prophylactic therapy 
significantly reduces the risk of developing haemophilic arthropathy, thus avoiding 
immobilization, crippling, and chronic pain (Manco-Johnson, 2007). Young patients with 
haemophilia that received prophylactic therapy had only slightly reduced bone mass 
(Barnes, 2004). Moreover, adult patients with haemophilia that received prophylactic 
treatment since childhood had bone mass comparable to patients with mild haemophilia 
(Khawaji, 2009.).  
2.3.6 Inhibitors 
Patients with inhibitors have significantly more joint pain with clinically and radiological 
worse orthopaedic status than patient without inhibitors (Morfini, 2007). Therefore, due to 
pathogenesis of osteoporosis in patient with haemophilia, they were expected to have lower 
bone mass than patients without inhibitors. Data about bone mineral mass in haemophilia 
patients with inhibitors in the literature are sparse. Only very few patients with inhibitors 
were evaluated. The study on 6 patients showed that patients with increased bone loss were 
statistically more likely to have a history of factor inhibitor (Gerstner, 2009). We have 
evaluated 9 patients with severe haemophilia and inhibitors. The results showed no 
difference in bone mineral mass between patients with severe haemophilia and with and 
without inhibitors. The discrepancy between those two studies may be explained by 
different treatment approaches. Moreover, in our study, no difference was found in number 
of target joints between patients with and without inhibitors, which can suggest effective 
treatment (Boban, unpublished data). 
2.3.7 Infection with hepatitis C 
Infection with hepatitis C virus (HCV) has been recognized as a risk factor for development 
of increased bone loss. HCV infection can lead to chronic liver disease, and consequently to 
increased bilirubin levels, hypogonadims and abnormalities in vitamin D metabolism, 
which can have negative influence on bone turnover (Olsson, 1994, Schiefke, 2005). 
Influence of HCV infection on bone loss in patients with haemophilia is still unclear. Two 
studies (Nair, 2007, Barnes, 2004) found no significant difference in bone mass between HCV 
positive and negative patients. On the other hand, Wallny showed significantly lower bone 
mass in heamophilia patients that were HCV positive (Wallny, 2007). According to our 
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study, HCV infection had no influence on bone mineral mass in patients with haemophilia. 
Nevertheless, slight difference was seen in group of patients with mild and moderate 
haemophilia, where we discovered negative influence of HCV infection on bone mineral 
(Boban, unpublished data). 
2.3.8 Quantitative ultrasound of the heel 
Dual energy X-ray absorptionmetry (DXA) is the golden standard for measurement of bone 
mineral mass. Quantitative ultrasound (QUS) of the heel is emerging as a new, low cost 
screening technique that is able to identify risk of osteoporotic fractures. The QUS 
parameters, BUA (broadband sound attenuation) and SOS (speed of sound) depend not 
only on mineral bone mass, but also on micro architecture and physical properties of bone 
tissue. A number of studies showed that the values of parameters measured with QUS are 
lower in woman with the history of osteoporotic fractures, regardless of the bone mineral 
density determined by DXA (Hernandez, 2004, Gluer, 2004). Thus, QUS parameters are 
independent risk indicator for hip fractures. Our study observed reduced bone properties 
among patients with severe hemophilia determined by QUS. On the other hand, patients 
with mild and moderate hemophilia had QUS values comparable to healthy controls. 
Sensitivity and specificity of QUS in finding reduced bone mineral density was 70,4% and 
64%, respectively. However, among studied population we observed no history of 
osteoporotic fractures. Therefore, we could not assess QUS as the method for identifying 
risk of osteoporotic fractures in patients with haemophilia (Boban, unpublished data). 
2.3.9 Haemophilia and bone mineral density  
Assessment of frequency of osteoporosis/osteopenia in patients with haemophilia A/B has 
been undertaken in National Haemophilia Centre. Results showed that patients with 
haemophilia have high risk of developing osteoporosis and osteopenia, which is dependent 
on severity of haemophilia, but not on presence of FVIII inhibitors or hepatitis C infection. 
Quantitative ultrasound of the heel, after modification of T- cut off values, showed high 
sensitivity and specificity for detection of reduced bone mineral density in haemophilia 
patients.  
3. Conclusion  
The improved diagnosis and comprehensive care of patients with hemophilia around the 
world have introduced the new problems of an aging patients with hemophilia and other 
co-morbidities. It is obvious that population of people with hemophilia is getting older, 
approaching life expectancy that of the general male population; at least in countries that 
can afford regular replacement therapy with coagulation factor concentrates.  
Such improvement of life expectancy among people with hemophilia is due to several 
factors: advances in hemophilia replacement treatment, comprehensive care, home 
treatment and prophylaxis, as well as due to advances in general health care improvement.  
Two investigations have been set in Hemophilia Centre. The first one was conducted  about 
the frequency of classical risk factors of coronary heart disease in patients with haemophilia 
A and B as well as new risk actors – homocysteine and lipoprotein (a).  
The frequencies of atherosclerotic complications are less expressed in haemophilia patients 
than expected from the data of the normal Croatian population  
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The results of investigated risk factors of CHD in patients’ with haemophilia reveal the 
importance to follow up in spite of the protection of haemophilia in clinical manifestations 
of atherosclerosis.  
Recently, Biere-Rafi (Biere-Rafi, 2011) also published data about cardiovascular risk 
assessment in haemophilia patients. They found that the number of hemophiliacs with 
hyperglycaemie (24%) and hypertension (51%) was higher than in the controls. It is 
comparable with our results that hemophiliacs have more arterial hypertension than the 
control group. Also, they have lower level of low-density lipoprotein (LDL) than control 
what is also comparable with our results.   
Considering high prevalence of patients with cardiovascular risk factors, active screening 
for these factors is recommended. 
The second investigation assessed the frequency of osteoporosis/osteopenia in patients with 
haemophilia A/B (see 2.3.9.). 
The aging haemophilia population will have much co-morbidities like older general 
population, however with specific complex requirements due to bleeding tendency. There 
are well established guidelines of care for the younger people with hemophilia, but it is 
necessary to have guidelines of care for aging hemophilia patients as well.   
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